The statement about Pfizer in the Nox press release is a little misleading. Pfizer bought the company Medivation for $14bn which yes gave it enzalutamide but Medivation also had a range of other oncology drugs in its portfolio like PARP inhibitor and a checkpoint inhibitor. IE the deal was about the whole asset pipeline not just enzalutamide. Not surprising as Pfizer is well behind and trying to play catch up in oncology
take your point about incorrect conflation
LuPIN abstract, page-24
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $11.03K | 105.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 418372 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 102513 | 3 |
View Market Depth
| Last trade - 15.45pm 27/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |